EZH2 and ovarian cancer: It has been shown that lncRNA-ATB inhibition decreases the enrichment of EZH2 in the CDX1, LATS2, FOXC1, and E-cadherin promoters and decreases the histone trimethylation of their promoters in ovarian cancer cells (Chen and An, 2021[16]).